EP2596366A4 - Polythérapie basée sur des inhibiteurs de mdm2 et efgr - Google Patents

Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Info

Publication number: EP2596366A4
Authority: EP; European Patent Office
Prior art keywords: mdm2; combination therapy; efgr; inhibitors; efgr inhibitors
Prior art date: 2010-07-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP11810417.3A

Other languages

German (de)

English (en)

Other versions

EP2596366A1 (fr

Inventor

Benjamin Mugrage

Ignatius Turchi

Matthew Sills

Jane Ong

John Allocco

Pam Wines

Margarita Bastos

Joseph P Errico

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ERRICO, JOSEPH P.

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-07-21

Filing date

2011-07-21

Publication date

2014-04-16

2011-01-06 Priority claimed from US12/986,146 external-priority patent/US8618302B2/en

2011-07-21 Application filed by Individual filed Critical Individual

2013-05-29 Publication of EP2596366A1 publication Critical patent/EP2596366A1/fr

2014-04-16 Publication of EP2596366A4 publication Critical patent/EP2596366A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP11810417.3A 2010-07-21 2011-07-21 Polythérapie basée sur des inhibiteurs de mdm2 et efgr Withdrawn EP2596366A4 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US36648010P	2010-07-21	2010-07-21
US12/986,146 US8618302B2 (en)	2010-01-06	2011-01-06	Methods and compositions of targeted drug development
PCT/US2011/020414 WO2011085126A2 (fr)	2010-01-06	2011-01-06	Méthodes et compositions pour le développement de médicaments ciblés
PCT/US2011/020418 WO2011085129A2 (fr)	2010-01-06	2011-01-06	Méthodes et compositions pour le développement de médicaments ciblés
PCT/US2011/044882 WO2012012653A1 (fr)	2010-07-21	2011-07-21	Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Publications (2)

Publication Number	Publication Date
EP2596366A1 EP2596366A1 (fr)	2013-05-29
EP2596366A4 true EP2596366A4 (fr)	2014-04-16

Family

ID=45497182

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11810417.3A Withdrawn EP2596366A4 (fr)	2010-07-21	2011-07-21	Polythérapie basée sur des inhibiteurs de mdm2 et efgr

Country Status (3)

Country	Link
EP (1)	EP2596366A4 (fr)
CA (1)	CA2805658C (fr)
WO (1)	WO2012012653A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2858565A1 (fr)	2011-12-07	2013-07-04	Duke University	Procedes d'identification et d'utilisation d'inhibiteurs de mdm2
IN2014DN11205A (fr)	2012-06-20	2015-10-02	Eutropics Pharmaceuticals Inc
EP2922544B1 (fr)	2012-11-21	2018-08-01	Eutropics Pharmaceuticals, Inc.	Méthodes et compositions utiles dans le traitement de maladies faisant appel à des protéines de la famille bcl-2 avec des dérivés de quinoléine
WO2015017788A1 (fr)	2013-08-01	2015-02-05	Eutropics Pharmaceuticals, Inc.	Méthode permettant de prédire la sensibilité d'un cancer
AU2014342269B2 (en)	2013-10-30	2020-02-27	Eutropics Pharmaceuticals, Inc.	Methods for determining chemosensitivity and chemotoxicity
EP3388419A1 (fr) *	2017-04-12	2018-10-17	Leadiant Biosciences SA	Inhibiteurs de gli1 et utilisations associées

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009037343A1 (fr) *	2007-09-21	2009-03-26	Janssen Pharmaceutica Nv	Inhibiteurs de l'interaction entre mdm2 et p53
WO2009117484A2 (fr) *	2008-03-18	2009-09-24	University Of South Florida	Petite molécule inhibitrice d'e2f
US20100160313A1 (en) *	2008-10-22	2010-06-24	University Of Southern California	Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (fr) *	2009-12-31	2011-07-07	Zacharon Pharmaceuticals, Inc.	Inhibiteurs de glycosaminoglycane
WO2011085126A2 (fr) *	2010-01-06	2011-07-14	Errico Joseph P	Méthodes et compositions pour le développement de médicaments ciblés

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007107545A1 (fr) *	2006-03-22	2007-09-27	Janssen Pharmaceutica N.V.	Dérivés d'alkylamine cyclique en tant qu'inhibiteurs de l'interaction entre mdm2 et p53
SG174772A1 (en) *	2006-09-11	2011-10-28	Curis Inc	Multi-functional small molecules as anti-proliferative agents

2011
- 2011-07-21 EP EP11810417.3A patent/EP2596366A4/fr not_active Withdrawn
- 2011-07-21 WO PCT/US2011/044882 patent/WO2012012653A1/fr not_active Ceased
- 2011-07-21 CA CA2805658A patent/CA2805658C/fr not_active Expired - Fee Related

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2009037343A1 (fr) *	2007-09-21	2009-03-26	Janssen Pharmaceutica Nv	Inhibiteurs de l'interaction entre mdm2 et p53
WO2009117484A2 (fr) *	2008-03-18	2009-09-24	University Of South Florida	Petite molécule inhibitrice d'e2f
US20100160313A1 (en) *	2008-10-22	2010-06-24	University Of Southern California	Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore
WO2011082175A2 (fr) *	2009-12-31	2011-07-07	Zacharon Pharmaceuticals, Inc.	Inhibiteurs de glycosaminoglycane
WO2011085126A2 (fr) *	2010-01-06	2011-07-14	Errico Joseph P	Méthodes et compositions pour le développement de médicaments ciblés

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERKSON R G ET AL: "Pilot screening programme for small molecule activators of p53", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, vol. 115, no. 5, 10 July 2005 (2005-07-10), pages 701 - 710, XP008129829, ISSN: 0020-7136, [retrieved on 20050223], DOI: 10.1002/IJC.20968 *
DUTTA ET AL: "Cellular responses to EGFR inhibitors and their relevance to cancer therapy", CANCER LETTERS, NEW YORK, NY, US, vol. 254, no. 2, 8 September 2007 (2007-09-08), pages 165 - 177, XP022182281, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2007.02.006 *
IAN R HARDCASTLE: "Inhibitors of the MDM2-p53 interaction as anticancer drugs", DRUGS OF THE FUTURE 2007, PROUS SCIENCE, vol. 32, no. 10, 1 January 2007 (2007-01-01), pages 883 - 896, XP007919174, DOI: 10.1358/DOF.2007.032.10.1131965 *
See also references of WO2012012653A1 *

Also Published As

Publication number	Publication date
CA2805658C (fr)	2016-12-13
WO2012012653A1 (fr)	2012-01-26
EP2596366A1 (fr)	2013-05-29
CA2805658A1 (fr)	2012-01-26

Publication	Publication Date	Title
GB201012175D0 (en)	2010-09-01	Procedure and mechanisms
IL249669B (en)	2020-05-31	Converted 5-fluoro-h1-pyrazolopyridines and their use
IL222481A0 (en)	2012-12-31	Combination therapy
IL221511A (en)	2015-04-30	Arilatriazolones associated with bis aryl and their use
EP2542086A4 (fr)	2013-09-04	Composés et utilisations thérapeutiques associées
EP2552323A4 (fr)	2013-09-25	Polythérapie
ZA201303776B (en)	2014-11-26	Bromodomain inhibitors and uses thereof
EP2523630A4 (fr)	2014-01-08	Systèmes et méthodes thérapeutiques en bariatrie
ZA201208173B (en)	2013-07-31	Peptices and their use
EP2579865A4 (fr)	2013-09-11	Thérapie de combinaison avec de la lisdexamphétamine et la guanfacine à libération prolongée
AP2013006947A0 (en)	2013-06-30	Compounds and their use
EP2648736A4 (fr)	2015-04-29	Composés cycloalkylguanidines inhibiteurs de la f1f0-atpase et leurs utilisations
IL212760A0 (en)	2011-08-31	Internal and external disc shunts alleviate back pain
HUE041512T2 (hu)	2019-05-28	Új kombináció és alkalmazás
EP2596366A4 (fr)	2014-04-16	Polythérapie basée sur des inhibiteurs de mdm2 et efgr
EP2624854A4 (fr)	2014-03-19	Modulateurs de la moésine et leurs utilisations
GB201011411D0 (en)	2010-08-18	Therapeutic compounds and their use
EP2629766A4 (fr)	2014-05-14	Polythérapie
GB201102226D0 (en)	2011-03-23	Inventions and therapy
GB201102222D0 (en)	2011-03-23	Inventions and therapy
GB201102210D0 (en)	2011-03-23	Inventions and therapy
GB201102213D0 (en)	2011-03-23	Inventions and therapy
GB201102215D0 (en)	2011-03-23	Inventions and therapy
GB201102216D0 (en)	2011-03-23	Inventions and therapy
GB201102234D0 (en)	2011-03-23	Inventions and therapy

Legal Events

Date	Code	Title	Description
2013-04-26	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-05-29	17P	Request for examination filed	Effective date: 20130117
2013-05-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-07-03	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ERRICO, JOSEPH P.
2013-10-30	DAX	Request for extension of the european patent (deleted)
2014-04-16	A4	Supplementary search report drawn up and despatched	Effective date: 20140319
2014-04-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/517 20060101ALI20140313BHEP Ipc: A61K 45/06 20060101ALI20140313BHEP Ipc: A61K 31/4709 20060101AFI20140313BHEP Ipc: A61P 35/00 20060101ALI20140313BHEP
2015-07-22	17Q	First examination report despatched	Effective date: 20150623
2016-05-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2016-06-08	18D	Application deemed to be withdrawn	Effective date: 20160105